Image via GN — ASX:RHC Ramsay Health Care
Last updated
Ramsay Health Care: Ma Activity
Brightware Care Group has acquired Attadale Rehabilitation Hospital from Ramsay Health Care, indicating divestment activity
Source: GN — ASX:RHC Ramsay Health Care
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in healthcare.
Market context: The wider read — a Talent Market Index of 105.9 (Hot), down 2.3 month-on-month — shows Oceania signal flow steady (-0.1pts).
Ramsay Health Care: 3 signals in the last 90 days — above the Healthcare median of 1 across 10 tracked companies; 0.3% of MitchelLake's Oceania signal flow; 4 tracked across 85 days.
Also at Ramsay Health Care →
More signals across Healthcare
Ma Activity · Americas
Vertex Pharmaceuticals →Vertex Pharmaceuticals announced acquisition of Crinetics Pharmaceuticals for $10 billion, gaining approved drug Palsonify (acromegaly) and pipeline candidates including congenital adrenal hyperplasia therapy.
Ma Activity · EMEA
King's College London →King's College London announced plans to merge with Cranfield University in 2027
Ma Activity · Americas
Apellis Pharmaceuticals →Apellis Pharmaceuticals was acquired by Biogen for $5.6 billion, indicating major integration and potential restructuring
Partnership · EMEA
Cleveland Clinic →Cleveland Clinic established a partnership with the National Basketball Players Association (NBPA) to provide sports medicine research and performance insights to NBA players at The Sanctuary offseason retreat in Spain. Clinic is presenting partner for Plyrs Performance Summit and co-established a Sports Data Labs committee to assess athlete health data and performance innovation.
Strategic Hiring · Americas
United States Air Force →Air Force stood up first rapidly deployable counter-drone units (~20 enlisted Airmen per unit) and announced new base defense job specialty code career path to address evolving drone threats.
Product Launch · Asia
Takeda →Takeda's dengue vaccine (TAK-003) received India's Drug Controller General of India (DCGI) marketing authorization approval, becoming India's first-ever approved dengue vaccine. The vaccine is approved for ages 4-60 without pre-vaccination testing, regardless of previous dengue exposure.
Intelligence powered by Autonodal ↗